BRPI0916973A2 - anticorpos para ccr2 - Google Patents

anticorpos para ccr2

Info

Publication number: BRPI0916973A2
Authority: BR; Brazil
Prior art keywords: ccr2; antibodies
Prior art date: 2008-08-18

Application number

BRPI0916973A

Other languages

English (en)

Inventor

Arvind Rajpal

Bradley T Keller

Larry L Green

Laurie A Tylaska

Meina Liang

Ronald P Gladue

Shelley Sims Belouski

Shinji Ogawa

Original Assignee

Amgen Fremont Inc

Pfizer

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2008-08-18

Filing date

2009-08-17

Publication date

2016-07-26

2009-08-17 Application filed by Amgen Fremont Inc, Pfizer filed Critical Amgen Fremont Inc

2016-07-26 Publication of BRPI0916973A2 publication Critical patent/BRPI0916973A2/pt

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2869—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against hormone receptors
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/53—Hinge
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Organic Chemistry (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Engineering & Computer Science (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Bioinformatics & Cheminformatics (AREA)
Immunology (AREA)
Molecular Biology (AREA)
Virology (AREA)
Biomedical Technology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Genetics & Genomics (AREA)
Biophysics (AREA)
Biochemistry (AREA)
Oncology (AREA)
Communicable Diseases (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Diabetes (AREA)
Cardiology (AREA)
Heart & Thoracic Surgery (AREA)
Obesity (AREA)
Endocrinology (AREA)
Hematology (AREA)
Pain & Pain Management (AREA)
Rheumatology (AREA)
Ophthalmology & Optometry (AREA)
Biotechnology (AREA)
Hospice & Palliative Care (AREA)
Transplantation (AREA)
Emergency Medicine (AREA)

BRPI0916973A 2008-08-18 2009-08-17 anticorpos para ccr2 BRPI0916973A2 (pt)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US18935708P	2008-08-18	2008-08-18
PCT/US2009/004711 WO2010021697A2 (en)	2008-08-18	2009-08-17	Antibodies to ccr2

Publications (1)

Publication Number	Publication Date
BRPI0916973A2 true BRPI0916973A2 (pt)	2016-07-26

Family

ID=41347729

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
BRPI0916973A BRPI0916973A2 (pt)	2008-08-18	2009-08-17	anticorpos para ccr2

Country Status (21)

Country	Link
US (2)	US8710191B2 (pt)
EP (1)	EP2321351B1 (pt)
JP (1)	JP5685535B2 (pt)
KR (1)	KR101772706B1 (pt)
CN (1)	CN102239180B (pt)
AU (1)	AU2009283199B2 (pt)
BR (1)	BRPI0916973A2 (pt)
CA (1)	CA2734578C (pt)
CO (1)	CO6351802A2 (pt)
DK (1)	DK2321351T3 (pt)
ES (1)	ES2658117T3 (pt)
IL (1)	IL211284A (pt)
MX (1)	MX2011001911A (pt)
MY (1)	MY160892A (pt)
NO (1)	NO2321351T3 (pt)
NZ (1)	NZ591471A (pt)
PE (1)	PE20110774A1 (pt)
RU (1)	RU2547595C2 (pt)
SG (2)	SG10201701323TA (pt)
WO (1)	WO2010021697A2 (pt)
ZA (1)	ZA201101047B (pt)

Families Citing this family (55)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO2011116299A2 (en) *	2010-03-18	2011-09-22	Colorado State University Research Foundation	Myeloid derived suppressor cell inhibiting agents
US20110038871A1 (en) *	2009-08-11	2011-02-17	Veena Viswanth	Ccr2 inhibitors for treating conditions of the eye
CA2824060C (en) *	2011-01-10	2021-05-11	Novimmune S.A.	Anti-tlr4 antibodies and methods of use thereof
CN102603649B (zh) *	2011-01-20	2016-05-25	赣南师范学院	一种以地巴唑为先导分子的荧光探针化合物及其制备方法
US20120288442A1 (en) *	2011-05-11	2012-11-15	Atomic Energy Council-Institute Of Nuclear Energy Research	Nuclear Imaging Method Using Molecular Target Detection Agent for Liver Fibrosis
WO2012172342A2 (en)	2011-06-13	2012-12-20	Ith Immune Therapy Holdings	Treating multiple sclerosis
WO2012172343A2 (en)	2011-06-13	2012-12-20	Ith Immune Therapy Holdings	Treating primary sclerosing cholangitis
WO2012172336A2 (en)	2011-06-13	2012-12-20	Ith Immune Therapy Holdings	Treating inflammatory skin diseases
US9726666B2 (en)	2011-06-13	2017-08-08	Tla Targeted Immunotherapies Ab	Diagnosing and treating inflammatory diseases
WO2013041833A1 (en)	2011-06-13	2013-03-28	Ith Immune Therapy Holdings Ab	Treating conditions associated with metabolic syndrome
DK2718312T3 (en)	2011-06-13	2018-10-15	Tla Targeted Immunotherapies Ab	TREATMENT OF CONDITIONS CONNECTED WITH SEPSIS
DK2718313T3 (en)	2011-06-13	2017-08-28	Tla Targeted Immunotherapies Ab	TREATMENT OF RESPIRATORY CONDITIONS
WO2012172339A2 (en)	2011-06-13	2012-12-20	Ith Immune Therapy Holdings	Treating inflammatory arthritis
WO2012172337A2 (en)	2011-06-13	2012-12-20	Ith Immune Therapy Holdings	Treating cardiovascular disease
US20140349321A1 (en) *	2011-12-16	2014-11-27	Agency For Science, Technology And Research	Binding molecules against dengue virus and uses thereof
US9315579B2 (en)	2012-06-22	2016-04-19	Sorrento Therapeutics, Inc.	Antigen binding proteins that bind CCR2
US8975290B2 (en)	2013-03-01	2015-03-10	Colorado State University Research Foundation	Methods and compositions for enhancing an immune response, blocking monocyte migration, amplifying vaccine immunity and inhibiting tumor growth and metastasis
SG10201707855YA (en) *	2013-03-13	2017-10-30	Prothena Biosciences Ltd	Tau immunotherapy
NL2011406C2 (en)	2013-09-06	2015-03-10	Bionovion Holding B V	Method for obtaining april-binding peptides, process for producing the peptides, april-binding peptides obtainable with said method/process and use of the april-binding peptides.
WO2016081801A1 (en) *	2014-11-21	2016-05-26	Millennium Pharmaceuticals, Inc.	Use of an anti-ccr2 antagonist in the treatment of an infectious disease
NL2014108B1 (en) *	2015-01-09	2016-09-30	Aduro Biotech Holdings Europe B V	Altered april binding antibodies.
WO2016135280A1 (en) *	2015-02-26	2016-09-01	Innovative Concepts In Drug Development	Diagnostic markers of cognitive impairments, kits and uses thereof
PT3452507T (pt)	2016-05-02	2022-12-20	Prothena Biosciences Ltd	Imunoterapia anti-tau
EP3452508A1 (en)	2016-05-02	2019-03-13	Prothena Biosciences Limited	Antibodies recognizing tau
CU24538B1 (es)	2016-05-02	2021-08-06	Prothena Biosciences Ltd	Anticuerpos monoclonales que compiten por unirse a tau humano con el anticuerpo 16g7
CN115154467B (zh) *	2016-06-03	2024-08-23	坎莫森特里克斯公司	治疗肝纤维化的方法
MX2021014356A (es)	2016-11-23	2022-11-24	Chemocentryx Inc	Metodo para tratar glomeruloesclerosis segmentaria focal.
EP4252629A3 (en)	2016-12-07	2023-12-27	Biora Therapeutics, Inc.	Gastrointestinal tract detection methods, devices and systems
WO2018112264A1 (en)	2016-12-14	2018-06-21	Progenity Inc.	Treatment of a disease of the gastrointestinal tract with a chemokine/chemokine receptor inhibitor
EP3612563A1 (en)	2017-04-19	2020-02-26	Elstar Therapeutics, Inc.	Multispecific molecules and uses thereof
EP3620531A4 (en)	2017-05-02	2021-03-17	National Center of Neurology and Psychiatry	METHOD OF PREDICTION AND EVALUATION OF THERAPEUTIC EFFECT IN DISEASES RELATING TO IL-6 AND NEUTROPHILS
JP7442790B2 (ja)	2017-05-02	2024-03-05	プロセナバイオサイエンシーズリミテッド	タウ認識抗体
BR112020007183A2 (pt)	2017-10-11	2020-09-24	Chemocentryx, Inc.	tratamento de glomeruloesclerose focal segmentado com antagonistas de ccr2
WO2019078344A1 (ja)	2017-10-20	2019-04-25	学校法人兵庫医科大学	抗ｉｌ－６受容体抗体を含有する術後の癒着を抑制するための医薬組成物
JP7348899B2 (ja)	2017-12-08	2023-09-21	マレンゴ・セラピューティクス，インコーポレーテッド	多重特異性分子及びその使用
CA3085785A1 (en)	2017-12-19	2019-06-27	Surrozen, Inc.	Anti-lrp5/6 antibodies and methods of use
EP3732201A4 (en)	2017-12-19	2022-04-20	Surrozen Operating, Inc.	WNT SURROGATES AND THEIR USES
EP3818010A4 (en)	2018-07-03	2022-08-17	Fennec Pharmaceuticals, Inc.	Anhydrous sodium thiosulfate and formulations thereof
JP2021534101A (ja)	2018-08-09	2021-12-09	ヴェルソーセラピューティクス，インコーポレイテッド	Ｃｃｒ２及びｃｓｆ１ｒを標的とするためのオリゴヌクレオチド組成物ならびにその使用
EP3856350A1 (en)	2018-09-27	2021-08-04	Marengo Therapeutics, Inc.	Csf1r/ccr2 multispecific antibodies
CN116726361A (zh)	2018-11-19	2023-09-12	比奥拉治疗股份有限公司	用生物治疗剂治疗疾病的方法和装置
CN113396161A (zh) *	2018-12-04	2021-09-14	诺华股份有限公司	针对cd3的结合分子及其用途
JP2022515424A (ja)	2018-12-24	2022-02-18	サノフイ	突然変異ｆａｂドメインを有する多重特異性結合タンパク質
WO2020148769A1 (en) *	2019-01-16	2020-07-23	Yeda Research And Development Co. Ltd. At The Weizmann Institute Of Science	Biomarker for cns disease modification
AU2020231366A1 (en)	2019-03-03	2021-08-12	Prothena Biosciences Limited	Antibodies recognizing tau
JP7501876B2 (ja) *	2019-04-17	2024-06-18	国立大学法人広島大学	Ｉｌ－６阻害剤及びｃｃｒ２阻害剤を組み合わせて投与することを特徴とする泌尿器がんの治療剤
WO2020232127A1 (en) *	2019-05-13	2020-11-19	The Research Foundation For The State University Of New York	Compositions and methods to block and bind ccr2 to modulate cellular function
JP2022538222A (ja) *	2019-06-26	2022-09-01	アムニクスファーマシューティカルズ，インコーポレイテッド	Ｅｇｆｒ抗原結合断片およびそれを含む組成物
WO2021119482A1 (en)	2019-12-13	2021-06-17	Progenity, Inc.	Ingestible device for delivery of therapeutic agent to the gastrointestinal tract
US12319958B2 (en) *	2020-07-21	2025-06-03	Rutgers, The State University Of New Jersey	Method and kit for CCR2 expression profiling and disease stratification
US20220168330A1 (en)	2020-11-09	2022-06-02	Takeda Pharmaceutical Company Limited	Antibody drug conjugates
CN118159562A (zh)	2021-10-27	2024-06-07	花岗岩生物股份公司	靶向ccr2的抗体
CN114990073A (zh) *	2022-05-27	2022-09-02	河南农业大学	一种抗猪ccl2蛋白的单克隆抗体及其制备方法和应用
WO2024245988A1 (en)	2023-05-29	2024-12-05	Granite Bio Ag	Antibodies targeting ccr2
CN116510020A (zh) *	2023-06-01	2023-08-01	中国人民解放军军事科学院军事医学研究院	降低ccr2含量或活性的物质在治疗或预防发热伴血小板减少综合征中的应用

Family Cites Families (48)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB8823869D0 (en)	1988-10-12	1988-11-16	Medical Res Council	Production of antibodies
US5175384A (en)	1988-12-05	1992-12-29	Genpharm International	Transgenic mice depleted in mature t-cells and methods for making transgenic mice
US6673986B1 (en)	1990-01-12	2004-01-06	Abgenix, Inc.	Generation of xenogeneic antibodies
US6075181A (en)	1990-01-12	2000-06-13	Abgenix, Inc.	Human antibodies derived from immunized xenomice
ATE139258T1 (de)	1990-01-12	1996-06-15	Cell Genesys Inc	Erzeugung xenogener antikörper
US6150584A (en)	1990-01-12	2000-11-21	Abgenix, Inc.	Human antibodies derived from immunized xenomice
US5633425A (en)	1990-08-29	1997-05-27	Genpharm International, Inc.	Transgenic non-human animals capable of producing heterologous antibodies
US5814318A (en)	1990-08-29	1998-09-29	Genpharm International Inc.	Transgenic non-human animals for producing heterologous antibodies
US5770429A (en)	1990-08-29	1998-06-23	Genpharm International, Inc.	Transgenic non-human animals capable of producing heterologous antibodies
US5625126A (en)	1990-08-29	1997-04-29	Genpharm International, Inc.	Transgenic non-human animals for producing heterologous antibodies
AU664976B2 (en)	1990-08-29	1995-12-14	Gene Pharming Europe Bv	Homologous recombination in mammalian cells
US5661016A (en)	1990-08-29	1997-08-26	Genpharm International Inc.	Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5789650A (en)	1990-08-29	1998-08-04	Genpharm International, Inc.	Transgenic non-human animals for producing heterologous antibodies
ATE158021T1 (de)	1990-08-29	1997-09-15	Genpharm Int	Produktion und nützung nicht-menschliche transgentiere zur produktion heterologe antikörper
US5545806A (en)	1990-08-29	1996-08-13	Genpharm International, Inc.	Ransgenic non-human animals for producing heterologous antibodies
AU2515992A (en)	1991-08-20	1993-03-16	Genpharm International, Inc.	Gene targeting in animal cells using isogenic dna constructs
EP0619738B1 (en)	1991-12-02	2003-07-09	Millennium Pharmaceuticals, Inc.	Inhibitory immunoglobulin polypeptides to human pdgf beta receptor
ATE381614T1 (de)	1992-07-24	2008-01-15	Amgen Fremont Inc	Bildung von xenogenen antikörpern
US5643763A (en)	1994-11-04	1997-07-01	Genpharm International, Inc.	Method for making recombinant yeast artificial chromosomes by minimizing diploid doubling during mating
US6130364A (en)	1995-03-29	2000-10-10	Abgenix, Inc.	Production of antibodies using Cre-mediated site-specific recombination
US6091001A (en)	1995-03-29	2000-07-18	Abgenix, Inc.	Production of antibodies using Cre-mediated site-specific recombination
KR100479146B1 (ko)	1995-04-21	2005-05-16	셀 제네시스, 인코포레이티드	큰게놈dna결실유발법
EP1978033A3 (en)	1995-04-27	2008-12-24	Amgen Fremont Inc.	Human antibodies derived from immunized xenomice
EP0823941A4 (en)	1995-04-28	2001-09-19	Abgenix Inc	HUMAN ANTIBODIES DERIVED FROM IMMUNIZED XENO MOUSES
SE9600820D0 (sv)	1996-03-01	1996-03-01	Pharmacia Ab	Antibodies and their use
US5714352A (en)	1996-03-20	1998-02-03	Xenotech Incorporated	Directed switch-mediated DNA recombination
US5994619A (en)	1996-04-01	1999-11-30	University Of Massachusetts, A Public Institution Of Higher Education Of The Commonwealth Of Massachusetts, As Represented By Its Amherst Campus	Production of chimeric bovine or porcine animals using cultured inner cell mass cells
US5916771A (en)	1996-10-11	1999-06-29	Abgenix, Inc.	Production of a multimeric protein by cell fusion method
AU5702298A (en)	1996-12-03	1998-06-29	Abgenix, Inc.	Transgenic mammals having human Ig loci including plural VH and VK regions nd antibodies produced therefrom
US6235883B1 (en)	1997-05-05	2001-05-22	Abgenix, Inc.	Human monoclonal antibodies to epidermal growth factor receptor
AU2978899A (en)	1998-03-03	1999-09-20	Abgenix, Inc.	Cd147 binding molecules as therapeutics
US20020029391A1 (en)	1998-04-15	2002-03-07	Claude Geoffrey Davis	Epitope-driven human antibody production and gene expression profiling
US6312689B1 (en) *	1998-07-23	2001-11-06	Millennium Pharmaceuticals, Inc.	Anti-CCR2 antibodies and methods of use therefor
US6727349B1 (en) *	1998-07-23	2004-04-27	Millennium Pharmaceuticals, Inc.	Recombinant anti-CCR2 antibodies and methods of use therefor
US20020142374A1 (en)	1998-08-17	2002-10-03	Michael Gallo	Generation of modified molecules with increased serum half-lives
SI1141028T1 (sl)	1998-12-23	2010-05-31	Pfizer	Človeška monoklonska protitelesa proti CTLA
AU3327701A (en)	2000-02-03	2001-08-14	Millennium Pharm Inc	Humanized anti-ccr2 antibodies and methods of use therefor
GB0016138D0 (en)	2000-06-30	2000-08-23	Novartis Ag	Organic compounds
US20030165988A1 (en) *	2002-02-08	2003-09-04	Shaobing Hua	High throughput generation of human monoclonal antibody against peptide fragments derived from membrane proteins
EP2298717B1 (en)	2001-11-30	2015-10-28	Biogen MA Inc.	Antibodies against monocyte chemotactic proteins
AU2003209059A1 (en) *	2002-02-08	2003-09-02	Genetastix Corporation	Human monoclonal antibodies against membrane proteins
WO2004016769A2 (en)	2002-08-19	2004-02-26	Abgenix, Inc.	Antibodies directed to monocyte chemo-attractant protein-1 (mcp-1) and uses thereof
WO2004024921A1 (ja)	2002-09-12	2004-03-25	Juridical Foundation The Chemo-Sero-Therapeutic Research Institute	ヒト抗ヒトｍｃｐ−１抗体及び該抗体フラグメント
AU2003300896A1 (en)	2003-12-10	2005-07-14	Millennium Pharmaceuticals, Inc.	Humanized anti-ccr2 antibodies and methods of use
MXPA06014075A (es)	2004-06-03	2007-03-15	Novimmune Sa	Anticuerpos anti-cd3 y metodos de uso de los mismos.
EP1784425A4 (en)	2004-06-30	2009-02-18	Centocor Inc	ANTI-MCP-1 ANTIBODIES, COMPOSITIONS, METHODS AND USES
CN101005855A (zh)	2004-07-30	2007-07-25	辉瑞产品公司	治疗由ccr2介导的疾病或紊乱的方法
CA2665808A1 (en)	2006-10-05	2008-05-22	Centocor Ortho Biotech Inc.	Ccr2 antagonists for treatment of fibrosis

2009
- 2009-08-17 CA CA2734578A patent/CA2734578C/en active Active
- 2009-08-17 WO PCT/US2009/004711 patent/WO2010021697A2/en active Application Filing
- 2009-08-17 ES ES09789161.8T patent/ES2658117T3/es active Active
- 2009-08-17 MX MX2011001911A patent/MX2011001911A/es active IP Right Grant
- 2009-08-17 BR BRPI0916973A patent/BRPI0916973A2/pt not_active IP Right Cessation
- 2009-08-17 JP JP2011523807A patent/JP5685535B2/ja active Active
- 2009-08-17 DK DK09789161.8T patent/DK2321351T3/en active
- 2009-08-17 MY MYPI2011000512A patent/MY160892A/en unknown
- 2009-08-17 EP EP09789161.8A patent/EP2321351B1/en active Active
- 2009-08-17 NO NO09789161A patent/NO2321351T3/no unknown
- 2009-08-17 NZ NZ591471A patent/NZ591471A/xx unknown
- 2009-08-17 US US13/059,702 patent/US8710191B2/en active Active
- 2009-08-17 AU AU2009283199A patent/AU2009283199B2/en not_active Ceased
- 2009-08-17 CN CN200980136307.1A patent/CN102239180B/zh not_active Expired - Fee Related
- 2009-08-17 KR KR1020117006355A patent/KR101772706B1/ko active Active
- 2009-08-17 SG SG10201701323TA patent/SG10201701323TA/en unknown
- 2009-08-17 RU RU2011110169/10A patent/RU2547595C2/ru active
- 2009-08-17 PE PE2011000160A patent/PE20110774A1/es active IP Right Grant
- 2009-08-17 SG SG2013063318A patent/SG193216A1/en unknown
2011
- 2011-02-09 ZA ZA2011/01047A patent/ZA201101047B/en unknown
- 2011-02-17 IL IL211284A patent/IL211284A/en active IP Right Grant
- 2011-03-11 CO CO11030038A patent/CO6351802A2/es active IP Right Grant
2014
- 2014-04-03 US US14/244,167 patent/US9238691B2/en active Active

Also Published As

Publication number	Publication date
CN102239180A (zh)	2011-11-09
CA2734578C (en)	2019-03-12
SG193216A1 (en)	2013-09-30
US9238691B2 (en)	2016-01-19
CO6351802A2 (es)	2011-12-20
CN102239180B (zh)	2014-12-31
KR101772706B1 (ko)	2017-08-29
NZ591471A (en)	2012-08-31
CA2734578A1 (en)	2010-02-25
JP2012500020A (ja)	2012-01-05
KR20110057166A (ko)	2011-05-31
RU2547595C2 (ru)	2015-04-10
HK1163134A1 (en)	2012-09-07
AU2009283199A8 (en)	2011-06-16
EP2321351B1 (en)	2017-11-01
WO2010021697A2 (en)	2010-02-25
IL211284A0 (en)	2011-04-28
SG10201701323TA (en)	2017-04-27
US8710191B2 (en)	2014-04-29
US20110274696A1 (en)	2011-11-10
EP2321351A2 (en)	2011-05-18
ES2658117T3 (es)	2018-03-08
NO2321351T3 (pt)	2018-03-31
AU2009283199B2 (en)	2015-08-13
JP5685535B2 (ja)	2015-03-18
MY160892A (en)	2017-03-31
AU2009283199A1 (en)	2010-02-25
WO2010021697A3 (en)	2010-09-16
ZA201101047B (en)	2012-04-25
IL211284A (en)	2017-07-31
MX2011001911A (es)	2011-07-04
PE20110774A1 (es)	2011-10-13
US20140342450A1 (en)	2014-11-20
DK2321351T3 (en)	2017-12-18
RU2011110169A (ru)	2012-09-27

Publication	Publication Date	Title
BRPI0916973A2 (pt)	2016-07-26	anticorpos para ccr2
CY2019004I1 (el)	2019-11-27	Τροποποιημενα αντισωματα αντι-ιl-23ρ19
SMT201600288B (it)	2016-11-10	SPECIFICI ANTICORPI IgE
BRPI0906877A2 (pt)	2015-07-28	Anticorpos anti-trkb aperfeiçoados
BRPI0907237A2 (pt)	2015-07-14	Anticorpo anti-cldn6
HRP20171011T1 (hr)	2017-09-22	ANTI-eMET ANTITIJELO
BRPI1014262A2 (pt)	2017-05-23	anticorpos específicos para caderina-17
PT2813570T (pt)	2018-02-12	Resumo
DK2340021T3 (da)	2012-12-10	Substituerede pyrrolidin-2-carboxamider
EP2473531A4 (en)	2013-05-01	Anti-gitr antibodies
BRPI1011005A2 (pt)	2018-03-06	anticorpos anti-epcam
DE602009000234D1 (de)	2010-11-11	msignals
EP2518338A4 (en)	2015-06-10	TERMINAL
EP2337798A4 (en)	2012-10-24	SPECIFIC ANTIBODIES OF THE ASB
PT3045471T (pt)	2017-06-14	Resumo
BRPI0914743A2 (pt)	2015-10-20	estrutura
HRP20150224T1 (xx)	2015-06-05	Anti-mif protutijela
DE602008003521D1 (de)	2010-12-30	Sitzrücklehnungsmechanismus
DK2342454T3 (da)	2013-10-28	Vindkraftanlæg
DK2335031T3 (da)	2019-08-26	In-line-måler
BRPI0909633A2 (pt)	2015-09-22	anticorpos anti-tyrp1
BRPI0819633A2 (pt)	2015-05-05	Métodos para produzir poliolefinas
FI20095459A0 (fi)	2009-04-24	Uusia määritysmenetelmiä
EP2360457A4 (en)	2014-08-27	Gas shutoff device
EP2416020A4 (en)	2013-05-01	TERMINAL

Legal Events

Date	Code	Title	Description
2018-01-23	B07D	Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
2018-04-17	B06F	Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
2019-12-17	B07E	Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
2020-02-27	B06U	Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
2021-04-27	B07A	Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
2021-06-08	B350	Update of information on the portal [chapter 15.35 patent gazette]
2021-06-22	B08F	Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]	Free format text: REFERENTE A 12A ANUIDADE.
2021-10-13	B08K	Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]	Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2633 DE 22-06-2021 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.